XXXX , REM @entity146 , and supranuclear gaze palsy associated with @entity15924 and @entity202 antibodies and @entity189 .

@entity1 @entity304 @entity202 @entity1640 @entity146 @entity16 @entity5 @entity189 @entity15924 @entity735 @entity2724 @entity2728 @entity51 @entity717 @entity7463 @entity25
OBJECTIVE: To describe a @entity1 with @entity1640 and mesencephalic presentation of a @entity15924 and @entity202 antibody-associated paraneoplastic @entity16 . DESIGN: Case report. SETTING: The Colorado Neurological Institute @entity717 Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. @entity1 : A 55-year-old @entity1 with a paraneoplastic @entity16 characterized by @entity735 movement @entity146 , @entity2724 , and a @entity7463 in the setting of @entity189 . INTERVENTION: Immunotherapy for paraneoplastic @entity16 , surgery and radiotherapy for @entity5 , and symptomatic treatment for @entity304 and @entity25 . MAIN OUTCOME MEASURES: Polysomnography, multiple sleep latency test, and neurological examination. RESULTS: The @entity5 was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with @entity2728 improved daytime somnolence. CONCLUSIONS: Rapid onset and progression of @entity51 may be a clue to paraneoplastic etiology. Early treatment of a limited stage @entity5 (with or without immunotherapy) may possibly slow progression of @entity16 . Symptomatic treatment may be beneficial.
